AbbVie Inc.
COMPANY DATA
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune…
PRICE HISTORY
1D
-1.3 %
1W
-1.4 %
1M
+2.1 %
6M
+15.6 %
YTD
+14.8 %
1Y
+25.9 %
2Y
+32.9 %
5Y
+119.4 %
10Y
+306 %
EARNINGS
Next earnings date
30/10/2026 (in 65 days)
Volatility around earnings
~16% stronger price swings than usual
SCORES
Valued significantly cheaper than its own historical average.
Very strong uptrend.
Average balance sheet quality.
Stable, well-covered dividend.
Weak growth or expensive relative to it.
Insiders are selling more shares than they buy.
Roughly meets expectations.
More upgrades than downgrades from analysts recently.
Very negative social media sentiment, swinging strongly.
Elevated short volume ratio.
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 26/08/2026.
ASK THE AGENTS ABOUT ABBV
ANALYST ASSESSMENT
PRICE TARGET LOW
US$235.00
CONSENSUS
US$285.92
MEDIAN
US$296.00
PRICE TARGET HIGH
US$303.00
0
STRONG BUY
30
BUY
11
HOLD
1
SELL
0
STRONG SELL
42
TOTAL · Buy
| DATE | ANALYST FIRM | RATING | ACTION |
|---|---|---|---|
| 20/08/2026 | Piper Sandler | Overweight | maintain |
| 17/08/2026 | Wells Fargo | Overweight | maintain |
| 13/08/2026 | Wolfe Research | Peer Perform → Outperform | upgrade |
| 11/08/2026 | BNP Paribas | Neutral | maintain |
| 10/08/2026 | Evercore ISI Group | Outperform | maintain |
| 04/08/2026 | Guggenheim | Buy | maintain |
| 03/08/2026 | Canaccord Genuity | Buy | maintain |
| 03/08/2026 | Cantor Fitzgerald | Overweight | maintain |
METRICS
P/E
73.91
P/B
-78.28
EV/EBITDA
24.85
RETURN ON EQUITY
-60.9 %
NET MARGIN
21.3 %
DEBT/EQUITY
-11.93
DIVIDEND YIELD
2.6 %
AS OF
30/06/2026
FREE FLOAT & LIQUIDITY
FREE FLOAT
99.8 %
FLOAT SHARES
1,763,612,594
AVG. DAILY VOLUME (30D)
5,103,276
INSIDER TRANSACTIONS (SEC)
| DATE | INSIDER | ROLE | TRANSACTION | SHARES | PRICE | PLAN TYPE |
|---|---|---|---|---|---|---|
| 18/08/2026 | Donoghoe Nicholas | Officer | Option exercise | 32,710 | 79.02 | Spontaneous |
| 18/08/2026 | Donoghoe Nicholas | Officer | Sale | 32,710 | 250 | Spontaneous |
| 12/05/2026 | FALK THOMAS J | Director | Grant | 1,118 | 0 | Spontaneous |
| 12/05/2026 | WADDELL FREDERICK H | Director | Grant | 1,118 | 0 | Spontaneous |
| 12/05/2026 | FREYMAN THOMAS C | Director | Grant | 1,118 | 0 | Spontaneous |
ATTENTION
1 mention today in US forums, about the same as yesterdayPrice since yesterday: -1.3%
Forums (Reddit)
INSTITUTIONAL HOLDERS
| FUND / INSTITUTION | SHARES | CHANGE | AS OF |
|---|---|---|---|
| BlackRock, Inc. | 149,488,412 | -1,209,713 | 30/06/2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | 115,396,098 | +515,774 | 30/06/2026 |
| STATE STREET CORP | 82,596,748 | +1,379,232 | 30/06/2026 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 48,477,996 | -1,045,082 | 30/06/2026 |
| JPMORGAN CHASE & CO | 47,862,796 | -8,878,895 | 30/06/2026 |
DIVIDENDS
| EX-DATE | PAY DATE | AMOUNT | YIELD |
|---|---|---|---|
| 15/07/2026 | 14/08/2026 | US$1.73 | 2.8 % |
| 15/04/2026 | 15/05/2026 | US$1.73 | 3.2 % |
| 16/01/2026 | 17/02/2026 | US$1.73 | 3.1 % |
| 15/10/2025 | 14/11/2025 | US$1.64 | 2.9 % |
| 15/07/2025 | 15/08/2025 | US$1.64 | 3.5 % |
Not investment advice. Past performance is not an indicator of future results.